Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palverafusp alfa - ImmuneOnco Biopharma

Next Previous
Drug Profile

Palverafusp alfa - ImmuneOnco Biopharma

Alternative Names: AXN-2510; IMM-2510; SYN-2510

Latest Information Update: 28 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuneOnco Biopharma
  • Developer Axion Bio; ImmuneOnco Biopharma; Instil Bio
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
  • No development reported Soft tissue sarcoma

Most Recent Events

  • 28 Sep 2025 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Late-stage disease, Monotherapy, Second-line therapy or greater) in China (IV, Infusion)
  • 15 Sep 2025 Phase-I clinical trials in Solid tumours (Monotherapy, Metastatic disease, Late-stage disease) in USA (IV) (NCT07159828)
  • 12 Sep 2025 ImmuneOnco Biopharma plans a phase-I/II trial for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (IV), in October 2025 (NCT07170787)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top